Citadel Advisors
CRBU icon

Citadel Advisors’s Caribou Biosciences CRBU Stock Holding History

Citadel Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60K Sell
34,100
-38,300
-53% -$75.7K ﹤0.01% 13029
2026
Q1 		$138K Buy
72,400
+3,600
+5% +$6.18K ﹤0.01% 11757
2025
Q4 		$109K Sell
68,800
-4,900
-7% -$10.3K ﹤0.01% 11560
2025
Q3 		$172K Buy
73,700
+34,800
+89% +$65.7K ﹤0.01% 11416
2025
Q2 		$49K Buy
38,900
+10,100
+35% +$9.93K ﹤0.01% 11777
2025
Q1 		$26.3K Sell
28,800
-38,600
-57% -$50.2K ﹤0.01% 12930
2024
Q4 		$107K Sell
67,400
-3,300
-5% -$6.64K ﹤0.01% 11378
2024
Q3 		$139K Buy
70,700
+300
+0.4% +$614 ﹤0.01% 10670
2024
Q2 		$115K Buy
70,400
+48,000
+214% +$153K ﹤0.01% 10711
2024
Q1 		$115K Buy
22,400
+20,000
+833% +$123K ﹤0.01% 11161
2023
Q4 		$13.8K Sell
2,400
-6,900
-74% -$34.1K ﹤0.01% 12912
2023
Q3 		$44.5K Sell
9,300
-11,400
-55% -$70.7K ﹤0.01% 11889
2023
Q2 		$88K Buy
20,700
+1,600
+8% +$7.19K ﹤0.01% 11120
2023
Q1 		$101K Buy
19,100
+12,300
+181% +$76.6K ﹤0.01% 11243
2022
Q4 		$42.7K Buy
+6,800
New +$60.5K ﹤0.01% 12325
2022
Q2 		– Sell
-12,100
Closed -$111K – 13008
2022
Q1 		$111K Buy
+12,100
New +$127K ﹤0.01% 12171

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors's CRBU Position: Q2 2026 in Review

Citadel Advisors reduced its Caribou Biosciences (CRBU) stake by 75% in Q2 2026, selling an estimated $234K and leaving 40,415 shares worth $71.1K. The position accounts for ﹤0.01% of the portfolio, ranked #12912.

Citadel Advisors first reported a position in CRBU in Q4 2021 and has held it in 16 quarters since. The position peaked at $3.28M in Q1 2022. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Citadel Advisors held 40,415 shares of Caribou Biosciences worth $71.1K as of Q2 2026.
  • Citadel Advisors sold 118,618 Caribou Biosciences shares in Q2 2026, an estimated $234K.
  • Caribou Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12912 holding.
  • Citadel Advisors first reported a position in Caribou Biosciences in Q4 2021 and has held it in 16 quarters since.
  • Citadel Advisors's Caribou Biosciences position peaked at $3.28M in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.